Conditional reimbursement within the Dutch drug policy

Health Policy

Volumn 84, Issue 1, 2007, Pages 39-50

  Niezen, Maartje ^a   de Bont, Antoinette ^a   Stolk, Elly ^a   Eyck, Arthur ^b   Niessen, Louis ^a   Stoevelaar, Herman ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ETC Crystal   (Netherlands)

Author keywords

Conditional reimbursement; Costs; Evaluation; Pharmaceuticals; The Netherlands

Indexed keywords

ACETYLCYSTEINE; ALGLUCERASE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; APRACLONIDINE; CLOPIDOGREL; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DORZOLAMIDE; ETIRACETAM; GABAPENTIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMIGLUCERASE; LAMOTRIGINE; LATANOPROST; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NON PRESCRIPTION DRUG; PALIVIZUMAB; PNEUMOCOCCUS VACCINE; RABIES VACCINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 2; RIVASTIGMINE; RUBELLA VACCINE; TOPIRAMATE; UNINDEXED DRUG;

ARTICLE; DRUG MARKETING; FEASIBILITY STUDY; HEALTH CARE POLICY; INTERVIEW; NETHERLANDS; PRESCRIPTION; QUALITATIVE RESEARCH; REIMBURSEMENT; TIME SERIES ANALYSIS;

INTERVIEWS AS TOPIC; LEGISLATION, DRUG; NATIONAL HEALTH PROGRAMS; NETHERLANDS; POLICY MAKING; QUALITATIVE RESEARCH; REIMBURSEMENT MECHANISMS;

EID: 34848903232     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.11.005     Document Type: Article

References (20)

1. Health Council. Medisch handelen op een tweesprong (Medicine in practice at a crossway) (1991), Health Council of The Netherlands, The Hague [in Dutch]
2. Stolk E.A., and Poleij M.J. Criteria for determining a basic health services package: recent developments in The Netherlands. European Journal Health Economics 6 1 (2005) 2-7
3. Health Care Insurance Board. Optimalisering nadere voorwaarden farmaceutische zorg (To optimize conditional reimbursement of pharmaceutical care) (2005), Health Care Insurance Board, Diemen [in Dutch]
4. van Oostenbruggen M.F., et al. Penny and pound wise. Pharmacoeconomics from a governmental perspective. Pharmacoeconomics 23 3 (2005) 219-226
5. Kooijman H.Z.V. Internationaal vergelijkend Onderzoek naar de Samenstelling van het Basispakket van de Nationale Ziektekostenverzekering (Health care insured. International comparative research on the composition of the benefit package) (2003), Pharmerit, Cappele ad IJssel [in Dutch]
6. Marx P. The reimbursement system of drugs in Germany. European Journal Health Economics 1 1 (2000) 11-15
7. Raftery J. NICE: faster guidance to modern treatments? Analysis of guidance of technologies. British Medical Journal 232 (2001) 1300-1303
8. Vuorenkoski L., Toiviainen H., and Hemminki E. Drug reimbursement in Finland: a case of explicit prioritising in special categories. Health Policy 66 2 (2003) 169-177
9. Niezen M., et al. Evaluatie van Bijlage 2 als beleidsinstrument (Evaluation of Schedule 2 as a policy measure) (2004), Institute of Health Policy and Management, Rotterdam, Erasmus MC [in Dutch]
10. Health Care Insurance Board. Procedure aanvraag vergoeding geneesmiddelen (Request procedure reimbursement of drugs) (2000), Health Care Insurance Board, Amstelveen [in Dutch]
11. Ministry of Health. Regeling Zorgverzekering (Regulation health insurance). Staatscourant 171 (2005) 15-64 [in Dutch]
12. Vlug A.E., van der Lei J., Mosseveld B.M., van Wijk M.A., van der Linden P.D., Sturkenboom M.C., and van Bemmel J.H. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 38 4-5 (1999) 339-344
13. Health Insurance Board. Rapport Beoordeling geneesmiddelen bij de ziekte van Alzheimer, rivastigmine (Excelon) (Report drug assessment for Alzheimer disease, rivastigmine (Excelon)) (1998), Health Insurance Board, Amstelveen [in Dutch]
14. Health Council. Cholesterol lowering therapy (2000), Health Council of The Netherlands, The Hague
15. Health Insurance Board. Protocol gebruik groeihormoon (Protocol growth hormone) (1997), Health Insurance Board, Amstelveen [in Dutch]
16. Health Insurance Board. CURE/99-28293 (1999), Health Insurance Board, Amstelveen [in Dutch]
17. Health Care Insurance Board. Protocol: Behandeling van korte lengte bij meisjes met Turner syndroom (Treatment of short length for girls with Turner syndrome) (1999), Health Care Insurance Board, Amstelveen [in Dutch]
18. Rikken F., and Eijgelshoven M. Evaluatie buiten-WTG maatregel (Evaluation 'buiten-WTG' regulation) (2000), Health Care Insurance Board, Amstelveen [in Dutch]
19. CBO. Behandeling en preventie van coronaire hartziekten door verlaging van de plasmacholesterolconcentratie. Consensus Cholesterol tweede herziening (Treatment and prevention of coronary heart disease using cholesterol lowering therapy. Consensus cholesterol. Second revision) (1998), Dutch Institute for Healthcare CBO, Utrecht [in Dutch]
20. Meeuwsisse-Mantel. Recent trends in (under)treatment of hypercholesterolaemia in The Netherlands. British Journal of Clinical Pharmacology 58 3 (2004) 310-316